← 治験一覧に戻る
CLL、3L+DLBCL、r/r ALL、および1L HR LBCLを対象としたRapcabtagene Autoleucelの第I/II相試験
基本情報
- NCT ID
- NCT03960840
- ステータス
- 実施中（募集終了）
- 試験のフェーズ
- 第1/第2相
- 試験タイプ
- 介入
- 目標被験者数
- 217
- 治験依頼者名
- Novartis
概要
This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).
対象疾患
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaDiffuse Large B-cell LymphomaAcute Lymphoblastic LeukemiaLarge B-cell Lymphoma
介入
Rapcabtagene autoleucel single agent(BIOLOGICAL)
Ibrutinib(DRUG)
依頼者（Sponsor）
ノバルティスファーマ株式会社(INDUSTRY)